Heparin-binding EGF-like growth factor (HB-EGF) antisense oligonucleotide protected against hyperlipidemia-associated...

Area of Science:

• Cardiovascular Research
• Metabolic Syndrome
• Molecular Biology

Background:

• Heparin-binding EGF-like growth factor (HB-EGF) is implicated in cellular stress responses and cardiovascular health.
• Previous studies demonstrated HB-EGF targeting with antisense oligonucleotide (ASO) reduces aortic aneurysm and improves lipid profiles.
• This study investigates HB-EGF ASO's impact on hyperlipidemia-driven atherosclerosis.

Purpose of the Study:

• To evaluate the therapeutic potential of HB-EGF ASO in an atherogenic mouse model.
• To determine the effect of HB-EGF ASO on lipid levels and atherosclerotic lesion development.
• To assess the impact of HB-EGF ASO on hepatic lipid production and insulin sensitivity.

Main Methods:

• Low-density lipoprotein receptor (LDLR) deficient mice were fed a Western diet for 12 weeks.
• Mice received cotreatment with control or HB-EGF ASOs.
• Hepatic very low-density lipoprotein (VLDL) production and glucose/insulin tolerance were assessed.

Main Results:

• HB-EGF ASO administration significantly reduced circulating VLDL and LDL levels.
• Atherosclerosis development in the aorta was markedly suppressed by HB-EGF ASO treatment.
• EGFR inhibition reduced hepatic triglyceride secretion, indicating HB-EGF's role in VLDL production.
• Insulin sensitivity and glucose tolerance were significantly improved in HB-EGF ASO-treated mice.

Conclusions:

• HB-EGF ASO effectively lowers circulatory lipid levels by reducing hepatic VLDL production.
• HB-EGF targeting provides protection against atherosclerosis in the vascular wall.
• HB-EGF ASO demonstrates potential as a therapeutic strategy for hyperlipidemia and associated metabolic dysfunction.